曲拉西利联合免疫联合化疗一线治疗广泛期小细胞肺癌1例及文献分析  

First⁃line trilaciclib combined with immunotherapy plus chemotherapy for extensive⁃stage small⁃cell lung cancer:a case report and literature review

作　　者：任冠颖 宋子正[1] 王小磊[1] 胡玲[1] 宋瑾[1] REN Guan-ying;SONG Zi-zheng;WANG Xiao-lei;HU Ling;SONG Jin(Department of Medical Oncology,Affiliated Hospital of Hebei University/Hebei Key Laboratory of Cancer Radiotherapy and Chemotherapy,Baoding 071000,China)

机构地区：[1]河北大学附属医院肿瘤内科/河北省肿瘤放化疗机制与规程研究重点实验室,保定071000

出　　处：《中国新药杂志》2023年第23期2366-2369,共4页Chinese Journal of New Drugs

摘　　要：小细胞肺癌是肺癌中恶性程度最高的一种分型,病情进展迅速,预后差,是临床上最难治愈的疾病之一。目前,含铂化疗仍然是广泛期小细胞肺癌(ES-SCLC)的一线标准治疗方案。足剂量化疗是获得最佳疗效的保证,一线治疗有效率达60%~80%(足剂量情况下),但化疗带来的骨髓抑制仍然是阻碍化疗的主要原因。目前,粒细胞集落刺激因子(G-CSF)在临床上常用于预防性升白治疗,但这种传统治疗手段可能造成骨髓造血储备功能耗竭,对患者正常骨髓造血功能产生损害。目前,曲拉西利已获批用于ES-SCLC骨髓抑制的预防治疗,能够从源头上保护造血干细胞/祖细胞(HSPCs)而起到保护骨髓的作用。本文特报道1例我科经治的ES-SCLC患者应用曲拉西利联合化疗进行骨髓保护的病例,以期提供进一步临床参考及依据。Small⁃cell lung cancer(SCLC)is one of the most malignant subtypes of lung cancer with rapid tumor progression and a poor prognosis,and also one of the malignancies most difficult to cure in clinical practice.Currently,platinum⁃based chemotherapy remains the first⁃line standard treatment for extensive⁃stage small cell lung cancer(ES⁃SCLC).Full⁃dose chemotherapy is warranted for the best efficacy,and the effective rate of first⁃line treatment is 60%~80%(full⁃dose),while chemotherapy⁃induced myelosuppression(CIM)is the main reason hindering adequate chemotherapy.Granulocyte colony⁃stimulating factor(G⁃CSF)is commonly used to deal with neutropenia in clinical practice,while this traditional treatment may even cause the depletion of bone marrow hematopoietic reserve function and damage to the normal bone marrow hematopoietic function of patients.Currently,trilaciclib has been approved for the prevention of myelosuppression in ES⁃SCLC,which can protect hematopoietic stem cells/progenitor cells(HSPCs)fundamentally.In this paper,we report a case of a patient with ES⁃SCLC treated in our department receiving bone marrow protection with trilaciclib combined with chemotherapy,aiming to provide reference and basis for further research.

关 键 词：广泛期小细胞肺癌 骨髓抑制 曲拉西利 细胞周期蛋白依赖性激酶4/6抑制剂 

分 类 号：R979.1[医药卫生—药品]